NCT03168698View on ClinicalTrials.gov

Carbetocin vs. Oxytocin at Elective Cesarean Section

NACompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

December 17, 2020

Study Completion Date

December 18, 2020

Conditions
Postpartum Hemorrhage
Interventions
DRUG

Carbetocin

Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

DRUG

Oxytocin

Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Trial Locations (2)

L8N 3Z5

McMaster University Medical Centre (MUMC), Hamilton

M5G1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT03168698 - Carbetocin vs. Oxytocin at Elective Cesarean Section | Biotech Hunter | Biotech Hunter